TreeFrog Therapeutics, a privately held French-based biotech startup focused on developing safe and affordable stem cell-derived cell therapies for millions of patients, today announced the successful closing of a $75 million (€64M) Series B financing round, bringing the total funding to date to $83 million...

TreeFrog Therapeutics announces the results of two runs of hiPSC amplification in 10L bioreactors at the Annual Meeting of the International Society for Stem Cell Research. BORDEAUX, France, Jun. 21, 2021 /PRNewswire/ -- Today, French cell therapy company TreeFrog Therapeutics released data showing the mass production of human...

Biomimetic 3D cell culture technology unlocks the manufacturing bottleneck of stem-cell derived cell therapies through exponential hiPSC growth in large-scale bioreactors, with best-in-class cell quality.  Bordeaux, France – April 13th, 2021. French cell therapy company TreeFrog Therapeutics announces unprecedented exponential growth of human induced pluripotent stem...